Ophthalmic Drugs Market

Ophthalmic Drugs Market (Therapeutic Class: Anti-VEGF Agents, Anti-glaucoma Drugs, Anti-inflammatory Drugs, Anti-infective Drugs, Anti-allergy Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Ophthalmic Drugs Market Outlook 2031

  • The global industry was valued at US$ 31.4 Bn in 2022
  • It is projected to grow at a CAGR of 6.2% from 2023 to 2031 and reach more than US$ 52.8 Bn by 2031

Analysts’ Viewpoint

Increase in prevalence of eye disorders and diseases is driving the global ophthalmic drugs market. Surge in incidence of eye conditions, such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy, due to aging population and changing lifestyles has led to higher demand for effective ophthalmic drugs to manage and treat these conditions. Furthermore, rise in healthcare expenditure and increase in awareness about eye health are likely to bolster global ophthalmic drugs market growth.

Advancements in technology and introduction of gene & stem cell therapies in ophthalmology offer lucrative opportunities to market players. Pharmaceutical companies are investing significantly in R&D to develop innovative drugs with enhanced therapeutic efficacy and improved delivery systems.

However, stringent regulatory requirements, high cost associated with drug development & clinical trials, availability of low-cost generic drugs, and high risk of adverse effects of drugs are likely to hamper the ophthalmic drugs industry growth during the forecast period.

Ophthalmic Drugs Market

Global Ophthalmic Drugs Market Introduction

Ophthalmic drugs are a category of pharmaceuticals specifically designed for the treatment, management, and prevention of eye disorders and diseases. These drugs are formulated to be administered directly to the eyes or their surrounding structures, typically in the form of eye drops, ointments, gels, or injections.

The field of ophthalmology encompasses a range of conditions, including but not limited to glaucoma, macular degeneration, diabetic retinopathy, dry eye, conjunctivitis, and ocular infections. Ophthalmic drugs are developed to address the specific needs of these conditions and provide therapeutic relief, improve vision, or slow down disease progression.

There are several categories of ophthalmic drugs, each targeting different aspects of eye health and functioning. Anti-inflammatory drugs are used to reduce inflammation in the eyes and provide relief from symptoms such as redness, swelling, and pain.

Anti-infective drugs, such as antibiotics and antivirals, are utilized to treat bacterial, viral, and fungal infections affecting the eyes. Anti-glaucoma drugs are designed to lower intraocular pressure, a major risk factor for glaucoma, to prevent further damage to the optic nerve. Anti-allergy drugs help manage allergic reactions that affect the eyes, such as itching, watering, and redness.

Development of ophthalmic drugs involves extensive research and clinical trials to ensure safety, efficacy, and proper delivery to the targeted ocular tissues. Formulation techniques are used to optimize drug delivery, such as creating sustained-release formulations that prolong drug release and reduce the frequency of administration. Combination therapies, which involve multiple active ingredients in a single formulation, are also being explored to enhance treatment outcomes and convenience for patients.

The global is driven by aging population, rise in prevalence of eye diseases, technological advancements, and surge in healthcare expenditure. Incidence of age-related eye disorders, such as cataracts and macular degeneration, is likely to increase due to rise in global geriatric population, which, in turn, is driving the demand for ophthalmic drugs.

Technological advancements in drug delivery systems, such as nanoparticles and implants, offer new avenues for targeted and sustained drug delivery to the eyes. Furthermore, increase in healthcare spending and rise in awareness about eye health are propelling global ophthalmic drugs market demand.

Rise in Prevalence of Eye Disorders and Diseases

Rise in prevalence of ophthalmic disorders and diseases is one of the key drivers of the ophthalmic drugs market size. Eye disorders, such as cataract, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and dry eye syndrome, are becoming more common.

This is ascribed to several factors such as aging population, unhealthy lifestyle choices, and increase in incidence of chronic diseases such as diabetes. If untreated, these eye conditions could cause vision impairment or even blindness, leading to rise in prevalence of the conditions.

According to the World Health Organization (WHO), over 2.2 billion people globally have some form of visual impairment or blindness. Of these, 1 billion people have a condition that could have been prevented or is yet to be treated. WHO estimates the number of people with vision impairment to triple by 2050, with the greatest increase in low- and middle-income countries.

According to the American Academy of Ophthalmology, the prevalence of age-related macular degeneration (AMD) is expected to increase from 196 million people in 2020 to 288 million people in 2040, an increase of 47% in just 20 years.

According to The International Myopia Institute, currently, around 30% of the world’s population has myopia and is expected to reach 50%, which is a staggering 5 billion people. The Glaucoma Research Foundation states that about 3 million individuals in the U.S. are affected by glaucoma, and the number is anticipated to rise to 4.2 million by 2030.

Increase in Awareness about Eye Health

Surge in awareness about eye health and the importance of early diagnosis and treatment is another key factor driving the global ophthalmic drugs market share. Awareness about eye health is increasing through education and outreach programs. For instance, the World Sight Day is an annual event held on the second Thursday of October to raise awareness about the importance of eye health.

Organizations such as the American Academy of Ophthalmology and the International Agency for the Prevention of Blindness run public education campaigns to spread awareness about eye health and encourage people to have regular eye check-ups.

Non-Governmental Organizations (NGOs) such as Orbis International, Sight Savers, and the International Agency for the Prevention of Blindness (IAPB) are working to increase awareness about eye health and provide eye care services to underserved populations.

In the U.S., the National Eye Institute runs the Healthy Vision Month campaign every May to encourage people to take care of their eyes and have regular eye exams.

The Fred Hollows Foundation, an international development organization, works to prevent and treat blindness and other vision problems in developing countries. The foundation provides training to local eye care workers and advocates for better eye health policies.

Governments and healthcare organizations across the world are investing in campaigns and initiatives to educate the public about the significance of regular eye checkups and timely intervention. This has led to increase in the number of patients seeking ophthalmic drugs for treatment.

Surge in Demand for Anti-VEGF Drugs

In terms of therapeutic class, the anti-VEGF segment accounted for major share of the global market in 2022. This is ascribed to increase in prevalence of ophthalmic diseases, including diabetic retinopathy, macular edema, age-related macular degeneration (AMD), and retinal vein occlusion, combined with surge in global geriatric population that is exposed to the risk of developing the condition.

Novel product launches across the globe are expected to fuel the segment. For example, in December 2022, Valitor announced a presentation on Multivalent Polymer Technology and Novel Anti-VEGF Antibody Conjugate Platform at the Ophthalmology Innovation Source Summit.

Availability of Promising Pipeline Products Fueling Retinal Disorders Segment

Based on indication, retinal disorders is projected to be a lucrative segment of the global ophthalmic drugs market during the forecast period.

Retinal disorders, such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion (RVO), are becoming more common across the world. This has led to increase in demand for effective treatments for these conditions.

Availability of promising pipeline products is anticipated to propel the retinal disorders segment during the analysis period. Moreover, nearly 11 million people in the U.S. have some form of AMD, while 1.1 million people, or 10%, have wet AMD. Nearly 200,000 new cases of wet AMD are diagnosed every year across the U.S. Diabetic retinopathy impacts nearly 7.7 million people in the country. The number is expected to increase to 11.3 million by 2030.

Increase in Demand for Eye Drops

In terms of dosage form, the eye drops segment is projected to dominate the global ophthalmic drugs market during the forecast period.

Increase in global geriatric population, which is more susceptible to eye illnesses, and surge in number of bacterial infection cases in youngsters are anticipated to propel the eye drops segment in the next few years.

Several novel innovations in eye drops, such as nanoparticle-based eye drops, preservative-free eye drops, and smart eye drops, are driving the segment. For instance, in August 2022, Alcon announced new addition to its advanced portfolio of dry-eye medications. The new ‘SYSTANE COMPLETE’ Preservative-Free eye drops is an all-in-one solution available in multi-dose and easy-to-use bottle.

In October 2021, Novaliq, a biopharmaceutical company specializing in innovative ocular therapeutics using their proprietary EyeSol technology, declared the adoption and implementation of a quality management system aligned with Annex IX, Chapter I of the EU Medical Device Regulation (MDR). This system was applied for assessing the compliance of their medical devices, namely NovaTears, NovaTears+Omega-3, and EvoTears OMEGA.

Regional Outlook

According to ophthalmic drugs market trends, North America is a significant market for ophthalmic drugs, with the U.S. being the largest contributor to market revenue. Increase in prevalence of common eye disorders and eye diseases across the region is one of the major factors driving the market during the forecast period.

According to the CDC, in the U.S. alone, around 12 million people aged 40 and older suffer from vision impairment, with about a million suffering from blindness.

In Canada, 5.5 million Canadians (1 in 7) have vision threatening eye conditions. Additionally, introduction of new and innovative ophthalmic drugs & therapies, increase in healthcare expenditure, and rise in awareness about eye health are propelling the market in the country.

Strong presence of prominent players, including Regeneron Pharmaceuticals Inc., Allergan/AbbVie, and Alcon Vision LLC, and their effective strategies are expected to drive the market in the region. Moreover, startup companies operating in the U.S. are entering into partnerships. For instance, in February 2023, Eyenovia and Formosa partnered for new ophthalmic therapeutics.

The market in Asia Pacific is projected to expand at the fastest CAGR during the forecast period. Expansion of the market in the region can be attributed to high disease prevalence, emergence of local companies, and presence of a large patient pool.

Asia Pacific has the largest patient base. Multiple strategic initiatives implemented by key drug manufacturers are projected to bolster market expansion in the region.

In July 2018, Novotech, Asia Pacific-centered global biotech CRO, announced partnership with the Asian Eye Institute, Inc. (AEI), the Philippines-based prominent eye center, in order to facilitate rapid and high-quality feasibility, recruitment processes, and start-up for its ophthalmology clients.

Analysis of Key Players in Global Ophthalmic Drugs Market

This report provides profiles of leading players operating in the global ophthalmic drugs market. These include AbbVie, Inc., Alcon Vision LLC, Bausch Health Companies, Inc., Bayer AG, Coherus BioSciences, F. Hoffmann-La Roche Ltd., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand presence and gain market share.

Key Developments in Global Ophthalmic Drugs Market

  • In April 2022, Sandoz, a Novartis division, announced the U.S. launch of the generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie's COMBIGAN, to lower eye pressure in patients with ocular hypertension
  • In January 2022, F. Hoffmann-La Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME)
  • In October 2021, the U.S. FDA approved AbbVie, Inc.’s Vuity (pilocarpine HCl ophthalmic solution) for the treatment of presbyopia. Vuity is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults.
  • In September 2021, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd., received an approval from the U.S. FDA for the first available generic version of AZOPT (brinzolamide ophthalmic suspension) 1% for the treatment of high pressure inside the eye due to ocular hypertension and open-angle glaucoma.

The ophthalmic drugs industry research report profiles the top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.

Global Ophthalmic Drugs Market Snapshot

Attribute

Detail

Size in 2022

US$ 31.4 Bn

Forecast (Value) in 2031

More than US$ 52.8 Bn

Growth Rate (CAGR)

6.2%

Forecast Period

2023-2031

Historical Data Available for

2017-2022

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Therapeutic Class
    • Anti-VEGF Agents
    • Anti-glaucoma Drugs
      • Alpha Agonist
      • Beta Blockers
      • Prostaglandin Analogs
      • Combined Medication
      • Others
    • Anti-inflammatory Drugs
      • Steroids
      • NSAIDs
    • Anti-infective Drugs
      • Anti-bacterial Drugs
      • Anti-fungal Drugs
      • Others
    • Anti-allergy Drugs
    • Others
  • Indication
    • Dry Eye
    • Glaucoma
    • Infection / Inflammation
    • Retinal Disorders
      • Wet AMD
      • Dry AMD
      • Diabetic Retinopathy
      • Others
    • Allergy
    • Uveitis
    • Others
  • Route of Administration
    • Topical
    • Local Ocular (intravitreal)
    • Others
  • Product Type
    • OTC
    • Prescription
  • Dosage Form
    • Eye Drops
    • Eye Solutions & Suspensions
    • Capsules & Tablets
    • Gels
    • Ointments
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AbbVie, Inc.
  • Alcon Vision LLC
  • Bausch Health Companies, Inc.
  • Bayer AG
  • Coherus BioSciences
  • F. Hoffmann-La Roche Ltd.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global ophthalmic drugs market in 2022?

The global market was valued at US$ 31.4 Bn in 2022

How big will be the ophthalmic drugs industry in 2031?

It is projected to reach more than US$ 52.8 Bn by 2031

How will the global ophthalmic drugs business grow during the forecast period?

It is anticipated to expand at a CAGR of 6.2% from 2023 to 2031

Which was the leading therapeutic class segment of the ophthalmic drugs?

The anti-VEGF agents segment accounted for the largest market share in 2022

Which region will account for major market share of the ophthalmic drugs during the forecast period?

North America is expected to account for the leading market share during the forecast period.

Who are the prominent ophthalmic drugs players?

AbbVie, Inc., Alcon Vision LLC, Bausch Health Companies, Inc., Bayer AG, Coherus BioSciences, F. Hoffmann-La Roche Ltd., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are the leading players in the global market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Ophthalmic Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Ophthalmic Drugs Market Volume Forecast, by Dosage Form, 2017-2031

    5. Key Insights

        5.1. Disease Prevalence & Incidence rate globally with key countries

        5.2. Pipeline Analysis

        5.3. Key Industry Events

        5.4. Covid-19 Pandemic Impact on the Industry

    6. Global Ophthalmic Drugs Market Analysis and Forecast, by Therapeutic Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Therapeutic Class, 2017-2031

            6.3.1. Anti-VEGF Agents

            6.3.2. Anti-glaucoma Drugs

                6.3.2.1. Alpha Agonist

                6.3.2.2. Beta Blockers

                6.3.2.3. Prostaglandin Analogs

                6.3.2.4. Combined Medication

                6.3.2.5. Others

            6.3.3. Anti-inflammatory Drugs

                6.3.3.1. Steroids

                6.3.3.2. NSAIDs

            6.3.4. Anti-infective Drugs

                6.3.4.1. Anti-bacterial Drugs

                6.3.4.2. Anti-fungal Drugs

                6.3.4.3. Others

            6.3.5. Anti-allergy Drugs

            6.3.6. Others

        6.4. Market Attractiveness Analysis, by Therapeutic Class

    7. Global Ophthalmic Drugs Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Indication, 2017-2031

            7.3.1. Dry Eye

            7.3.2. Glaucoma

            7.3.3. Infection/Inflammation

            7.3.4. Retinal Disorders

                7.3.4.1. Wet AMD

                7.3.4.2. Dry AMD

                7.3.4.3. Diabetic Retinopathy

                7.3.4.4. Others

            7.3.5. Allergy

            7.3.6. Uveitis

            7.3.7. Others

        7.4. Market Attractiveness Analysis, by Indication

    8. Global Ophthalmic Drugs Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Route of Administration, 2017-2031

            8.3.1. Topical

            8.3.2. Local Ocular (intravitreal)

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. Global Ophthalmic Drugs Market Analysis and Forecast, by Product Type

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Product Type, 2017-2031

            9.3.1. Prescription

            9.3.2. OTC

        9.4. Market Attractiveness Analysis, by Product Type

    10. Global Ophthalmic Drugs Market Analysis and Forecast, by Dosage Form

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Market Value Forecast, by Dosage Form, 2017-2031

            10.3.1. Eye Drops

            10.3.2. Eye Solutions & Suspensions

            10.3.3. Capsules & Tablets

            10.3.4. Gels

            10.3.5. Ointments

            10.3.6. Others

        10.4. Market Attractiveness Analysis, by Dosage Form

    11. Global Ophthalmic Drugs Market Analysis and Forecast, by Distribution Channel

        11.1. Introduction & Definition

        11.2. Key Findings / Developments

        11.3. Market Value Forecast, by Distribution Channel, 2017-2031

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

        11.4. Market Attractiveness Analysis, by Distribution Channel

    12. Global Ophthalmic Drugs Market Analysis and Forecast, by Region

        12.1. Key Findings

        12.2. Market Value Forecast, by Region

            12.2.1. North America

            12.2.2. Europe

            12.2.3. Asia Pacific

            12.2.4. Latin America

            12.2.5. Middle East & Africa

        12.3. Market Attractiveness Analysis, by Region

    13. North America Ophthalmic Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Therapeutic Class, 2017-2031

            13.2.1. Anti-VEGF Agents

            13.2.2. Anti-glaucoma Drugs

                13.2.2.1. Alpha Agonist

                13.2.2.2. Beta Blockers

                13.2.2.3. Prostaglandin Analogs

                13.2.2.4. Combined Medication

                13.2.2.5. Others

            13.2.3. Anti-inflammatory Drugs

                13.2.3.1. Steroids

                13.2.3.2. NSAIDs

            13.2.4. Anti-infective Drugs

                13.2.4.1. Anti-bacterial Drugs

                13.2.4.2. Anti-fungal Drugs

                13.2.4.3. Others

            13.2.5. Anti-allergy Drugs

            13.2.6. Others

        13.3. Market Value Forecast, by Indication, 2017-2031

            13.3.1. Dry Eye

            13.3.2. Glaucoma

            13.3.3. Infection/Inflammation

            13.3.4. Retinal Disorders

                13.3.4.1. Wet AMD

                13.3.4.2. Dry AMD

                13.3.4.3. Diabetic Retinopathy

                13.3.4.4. Others

            13.3.5. Allergy

            13.3.6. Uveitis

            13.3.7. Others

        13.4. Market Value Forecast, by Route of Administration, 2017-2031

            13.4.1. Topical

            13.4.2. Local Ocular (intravitreal)

            13.4.3. Others

        13.5. Market Value Forecast, by Product Type, 2017-2031

            13.5.1. Prescription

            13.5.2. OTC

        13.6. Market Value Forecast, by Dosage Form, 2017-2031

            13.6.1. Eye Drops

            13.6.2. Eye Solutions & Suspensions

            13.6.3. Capsules & Tablets

            13.6.4. Gels

            13.6.5. Ointments

            13.6.6. Others

        13.7. Market Value Forecast, by Distribution Channel, 2017-2031

            13.7.1. Hospital Pharmacies

            13.7.2. Retail Pharmacies

            13.7.3. Online Pharmacies

        13.8. Market Value Forecast, by Country, 2017-2031

            13.8.1. U.S.

            13.8.2. Canada

        13.9. Market Attractiveness Analysis

            13.9.1. By Therapeutic Class

            13.9.2. By Indication

            13.9.3. By Route of Administration

            13.9.4. By Product Type

            13.9.5. By Dosage Form

            13.9.6. By Distribution Channel

            13.9.7. By Country

    14. Europe Ophthalmic Drugs Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Therapeutic Class, 2017-2031

            14.2.1. Anti-VEGF Agents

            14.2.2. Anti-glaucoma Drugs

                14.2.2.1. Alpha Agonist

                14.2.2.2. Beta Blockers

                14.2.2.3. Prostaglandin Analogs

                14.2.2.4. Combined Medication

                14.2.2.5. Others

            14.2.3. Anti-inflammatory Drugs

                14.2.3.1. Steroids

                14.2.3.2. NSAIDs

            14.2.4. Anti-infective Drugs

                14.2.4.1. Anti-bacterial Drugs

                14.2.4.2. Anti-fungal Drugs

                14.2.4.3. Others

            14.2.5. Anti-allergy Drugs

            14.2.6. Others

        14.3. Market Value Forecast, by Indication, 2017-2031

            14.3.1. Dry Eye

            14.3.2. Glaucoma

            14.3.3. Infection/Inflammation

            14.3.4. Retinal Disorders

                14.3.4.1. Wet AMD

                14.3.4.2. Dry AMD

                14.3.4.3. Diabetic Retinopathy

                14.3.4.4. Others

            14.3.5. Allergy

            14.3.6. Uveitis

            14.3.7. Others

        14.4. Market Value Forecast, by Route of Administration, 2017-2031

            14.4.1. Topical

            14.4.2. Local Ocular (intravitreal)

            14.4.3. Others

        14.5. Market Value Forecast, by Product Type, 2017-2031

            14.5.1. Prescription

            14.5.2. OTC

        14.6. Market Value Forecast, by Dosage Form, 2017-2031

            14.6.1. Eye Drops

            14.6.2. Eye Solutions & Suspensions

            14.6.3. Capsules & Tablets

            14.6.4. Gels

            14.6.5. Ointments

            14.6.6. Others

        14.7. Market Value Forecast, by Distribution Channel, 2017-2031

            14.7.1. Hospital Pharmacies

            14.7.2. Retail Pharmacies

            14.7.3. Online Pharmacies

        14.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.8.1. Germany

            14.8.2. U.K.

            14.8.3. France

            14.8.4. Spain

            14.8.5. Italy

            14.8.6. Rest of Europe

        14.9. Market Attractiveness Analysis

            14.9.1. By Therapeutic Class

            14.9.2. By Indication

            14.9.3. By Route of Administration

            14.9.4. By Product Type

            14.9.5. By Dosage Form

            14.9.6. By Distribution Channel

            14.9.7. By Country/Sub-region

    15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Therapeutic Class, 2017-2031

            15.2.1. Anti-VEGF Agents

            15.2.2. Anti-glaucoma Drugs

                15.2.2.1. Alpha Agonist

                15.2.2.2. Beta Blockers

                15.2.2.3. Prostaglandin Analogs

                15.2.2.4. Combined Medication

                15.2.2.5. Others

            15.2.3. Anti-inflammatory Drugs

                15.2.3.1. Steroids

                15.2.3.2. NSAIDs

            15.2.4. Anti-infective Drugs

                15.2.4.1. Anti-bacterial Drugs

                15.2.4.2. Anti-fungal Drugs

                15.2.4.3. Others

            15.2.5. Anti-allergy Drugs

            15.2.6. Others

        15.3. Market Value Forecast, by Indication, 2017-2031

            15.3.1. Dry Eye

            15.3.2. Glaucoma

            15.3.3. Infection/Inflammation

            15.3.4. Retinal Disorders

                15.3.4.1. Wet AMD

                15.3.4.2. Dry AMD

                15.3.4.3. Diabetic Retinopathy

                15.3.4.4. Others

            15.3.5. Allergy

            15.3.6. Uveitis

            15.3.7. Others

        15.4. Market Value Forecast, by Route of Administration, 2017-2031

            15.4.1. Topical

            15.4.2. Local Ocular (intravitreal)

            15.4.3. Others

        15.5. Market Value Forecast, by Product Type, 2017-2031

            15.5.1. Prescription

            15.5.2. OTC

        15.6. Market Value Forecast, by Dosage Form, 2017-2031

            15.6.1. Eye Drops

            15.6.2. Eye Solutions & Suspensions

            15.6.3. Capsules & Tablets

            15.6.4. Gels

            15.6.5. Ointments

            15.6.6. Others

        15.7. Market Value Forecast, by Distribution Channel, 2017-2031

            15.7.1. Hospital Pharmacies

            15.7.2. Retail Pharmacies

            15.7.3. Online Pharmacies

        15.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.8.1. China

            15.8.2. Japan

            15.8.3. India

            15.8.4. Australia & New Zealand

            15.8.5. Rest of Asia Pacific

        15.9. Market Attractiveness Analysis

            15.9.1. By Therapeutic Class

            15.9.2. By Indication

            15.9.3. By Route of Administration

            15.9.4. By Product Type

            15.9.5. By Dosage Form

            15.9.6. By Distribution Channel

            15.9.7. By Country/Sub-region

    16. Latin America Ophthalmic Drugs Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast, by Therapeutic Class, 2017-2031

            16.2.1. Anti-VEGF Agents

            16.2.2. Anti-glaucoma Drugs

                16.2.2.1. Alpha Agonist

                16.2.2.2. Beta Blockers

                16.2.2.3. Prostaglandin Analogs

                16.2.2.4. Combined Medication

                16.2.2.5. Others

            16.2.3. Anti-inflammatory Drugs

                16.2.3.1. Steroids

                16.2.3.2. NSAIDs

            16.2.4. Anti-infective Drugs

                16.2.4.1. Anti-bacterial Drugs

                16.2.4.2. Anti-fungal Drugs

                16.2.4.3. Others

            16.2.5. Anti-allergy Drugs

            16.2.6. Others

        16.3. Market Value Forecast, by Indication, 2017-2031

            16.3.1. Dry Eye

            16.3.2. Glaucoma

            16.3.3. Infection/Inflammation

            16.3.4. Retinal Disorders

                16.3.4.1. Wet AMD

                16.3.4.2. Dry AMD

                16.3.4.3. Diabetic Retinopathy

                16.3.4.4. Others

            16.3.5. Allergy

            16.3.6. Uveitis

            16.3.7. Others

        16.4. Market Value Forecast, by Route of Administration, 2017-2031

            16.4.1. Topical

            16.4.2. Local Ocular (intravitreal)

            16.4.3. Others

        16.5. Market Value Forecast, by Product Type, 2017-2031

            16.5.1. Prescription

            16.5.2. OTC

        16.6. Market Value Forecast, by Dosage Form, 2017-2031

            16.6.1. Eye Drops

            16.6.2. Eye Solutions & Suspensions

            16.6.3. Capsules & Tablets

            16.6.4. Gels

            16.6.5. Ointments

            16.6.6. Others

        16.7. Market Value Forecast, by Distribution Channel, 2017-2031

            16.7.1. Hospital Pharmacies

            16.7.2. Retail Pharmacies

            16.7.3. Online Pharmacies

        16.8. Market Value Forecast, by Country/Sub-region,2017-2031

            16.8.1. Brazil

            16.8.2. Mexico

            16.8.3. Rest of Latin America

        16.9. Market Attractiveness Analysis

            16.9.1. By Therapeutic Class

            16.9.2. By Indication

            16.9.3. By Route of Administration

            16.9.4. By Product Type

            16.9.5. By Dosage Form

            16.9.6. By Distribution Channel

            16.9.7. By Country/Sub-region

    17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast

        17.1. Introduction

            17.1.1. Key Findings

        17.2. Market Value Forecast, by Therapeutic Class, 2017-2031

            17.2.1. Anti-VEGF Agents

            17.2.2. Anti-glaucoma Drugs

                17.2.2.1. Alpha Agonist

                17.2.2.2. Beta Blockers

                17.2.2.3. Prostaglandin Analogs

                17.2.2.4. Combined Medication

                17.2.2.5. Others

            17.2.3. Anti-inflammatory Drugs

                17.2.3.1. Steroids

                17.2.3.2. NSAIDs

            17.2.4. Anti-infective Drugs

                17.2.4.1. Anti-bacterial Drugs

                17.2.4.2. Anti-fungal Drugs

                17.2.4.3. Others

            17.2.5. Anti-allergy Drugs

            17.2.6. Others

        17.3. Market Value Forecast, by Indication, 2017-2031

            17.3.1. Dry Eye

            17.3.2. Glaucoma

            17.3.3. Infection/Inflammation

            17.3.4. Retinal Disorders

                17.3.4.1. Wet AMD

                17.3.4.2. Dry AMD

                17.3.4.3. Diabetic Retinopathy

                17.3.4.4. Others

            17.3.5. Allergy

            17.3.6. Uveitis

            17.3.7. Others

        17.4. Market Value Forecast, by Route of Administration, 2017-2031

            17.4.1. Topical

            17.4.2. Local Ocular (intravitreal)

            17.4.3. Others

        17.5. Market Value Forecast, by Product Type, 2017-2031

            17.5.1. Prescription

            17.5.2. OTC

        17.6. Market Value Forecast, by Dosage Form, 2017-2031

            17.6.1. Eye Drops

            17.6.2. Eye Solutions & Suspensions

            17.6.3. Capsules & Tablets

            17.6.4. Gels

            17.6.5. Ointments

            17.6.6. Others

        17.7. Market Value Forecast, by Distribution Channel, 2017-2031

            17.7.1. Hospital Pharmacies

            17.7.2. Retail Pharmacies

            17.7.3. Online Pharmacies

        17.8. Market Value Forecast, by Country/Sub-region, 2017-2031

            17.8.1. GCC Countries

            17.8.2. South Africa

            17.8.3. Rest of Middle East & Africa

        17.9. Market Attractiveness Analysis

            17.9.1. By Therapeutic Class

            17.9.2. By Indication

            17.9.3. By Route of Administration

            17.9.4. By Product Type

            17.9.5. By Dosage Form

            17.9.6. By Distribution Channel

            17.9.7. By Country/Sub-region

    18. Competition Landscape

        18.1. Market Player - Competition Matrix (by tier and size of companies)

        18.2. Market Share Analysis, by Company, 2022

        18.3. Company Profiles

            18.3.1. AbbVie, Inc.

                18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.1.2. Product Portfolio

                18.3.1.3. Financial Overview

                18.3.1.4. SWOT Analysis

                18.3.1.5. Strategic Overview

            18.3.2. Alcon Vision LLC

                18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.2.2. Product Portfolio

                18.3.2.3. Financial Overview

                18.3.2.4. SWOT Analysis

                18.3.2.5. Strategic Overview

            18.3.3. Bausch Health Companies, Inc.

                18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.3.2. Product Portfolio

                18.3.3.3. Financial Overview

                18.3.3.4. SWOT Analysis

                18.3.3.5. Strategic Overview

            18.3.4. Bayer AG

                18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.4.2. Product Portfolio

                18.3.4.3. Financial Overview

                18.3.4.4. SWOT Analysis

                18.3.4.5. Strategic Overview

            18.3.5. Coherus BioSciences

                18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.5.2. Product Portfolio

                18.3.5.3. Financial Overview

                18.3.5.4. SWOT Analysis

                18.3.5.5. Strategic Overview

            18.3.6. F. Hoffmann-La Roche Ltd.

                18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.6.2. Product Portfolio

                18.3.6.3. Financial Overview

                18.3.6.4. SWOT Analysis

                18.3.6.5. Strategic Overview

            18.3.7. Novartis Pharmaceuticals Corporation

                18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.7.2. Product Portfolio

                18.3.7.3. Financial Overview

                18.3.7.4. SWOT Analysis

                18.3.7.5. Strategic Overview

            18.3.8. Pfizer, Inc.

                18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.8.2. Product Portfolio

                18.3.8.3. Financial Overview

                18.3.8.4. SWOT Analysis

                18.3.8.5. Strategic Overview

            18.3.9. Regeneron Pharmaceuticals, Inc.

                18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.9.2. Product Portfolio

                18.3.9.3. Financial Overview

                18.3.9.4. SWOT Analysis

                18.3.9.5. Strategic Overview

            18.3.10. Santen, Inc.

                18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.10.2. Product Portfolio

                18.3.10.3. Financial Overview

                18.3.10.4. SWOT Analysis

                18.3.10.5. Strategic Overview

            18.3.11. Sun Pharmaceutical Industries Ltd.

                18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.11.2. Product Portfolio

                18.3.11.3. Financial Overview

                18.3.11.4. SWOT Analysis

                18.3.11.5. Strategic Overview

            18.3.12. Teva Pharmaceutical Industries Ltd.

                18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.12.2. Product Portfolio

                18.3.12.3. Financial Overview

                18.3.12.4. SWOT Analysis

                18.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Ophthalmic Drugs Market Volume (Prescriptions in Mn) Forecast, by Dosage Form, 2017-2031

    Table 02: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031

    Table 03: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031

    Table 04: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031

    Table 05: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031

    Table 06: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 07: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031

    Table 08: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 09: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031

    Table 10: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031

    Table 11: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 12: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 13: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 14: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031

    Table 15: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031

    Table 16: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031

    Table 17: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031

    Table 18: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 19: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031

    Table 20: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 21: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031

    Table 22: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031

    Table 23: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 24: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 25: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031

    Table 26: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031

    Table 27: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031

    Table 28: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031

    Table 29: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 30: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031

    Table 31: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 32: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031

    Table 33: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031

    Table 34: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 35: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 36: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031

    Table 37: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031

    Table 38: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031

    Table 39: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031

    Table 40: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 41: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031

    Table 42: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 43: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031

    Table 44: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031

    Table 45: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 46: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 47: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031

    Table 48: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031

    Table 49: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031

    Table 50: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031

    Table 51: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 52: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031

    Table 53: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 54: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031

    Table 55: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031

    Table 56: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 57: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 58: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031

    Table 59: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031

    Table 60: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031

    Table 61: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031

    Table 62: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 63: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031

    Table 64: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 65: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031

    Table 66: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031

    Table 67: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01: Global Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031

    Figure 02: Global Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031

    Figure 03: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-VEGF Agents, 2017-2031

    Figure 04: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-glaucoma Drugs, 2017-2031

    Figure 05: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-inflammatory Drugs, 2017-2031

    Figure 06: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-infective Drugs, 2017-2031

    Figure 07: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-allergy Drugs, 2017-2031

    Figure 08: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 09: Global Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 10: Global Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031

    Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Dry Eye, 2017-2031

    Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Glaucoma, 2017-2031

    Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Infection/Inflammation, 2017-2031

    Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Retinal Disorders, 2017-2031

    Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Allergy, 2017-2031

    Figure 16: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Uveitis 2017-2031

    Figure 17: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 18: Global Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 19: Global Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 20: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Topical, 2017-2031

    Figure 21: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Local Ocular (intravitreal), 2017-2031

    Figure 22: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 23: Global Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 24: Global Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 25: Global Ophthalmic Drugs Market Value (US$ Mn), by Prescription, 2017‒2031

    Figure 26: Global Ophthalmic Drugs Market Value (US$ Mn), by OTC, 2017‒2031

    Figure 27: Global Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 28: Global Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031

    Figure 29: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Eye Drops, 2017-2031

    Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Eye Solutions & Suspensions, 2017-2031

    Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Capsules & Tablets, 2017-2031

    Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Gels, 2017-2031

    Figure 33: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Ointments, 2017-2031

    Figure 34: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 35: Global Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 36: Global Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 37: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031

    Figure 38: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031

    Figure 39: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031

    Figure 40: Global Ophthalmic Drugs Market Value Share Analysis, by Region, 2022 and 2031

    Figure 41: Global Ophthalmic Drugs Market Attractiveness Analysis, by Region, 2023-2031

    Figure 42: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031

    Figure 43: North America Ophthalmic Drugs Market Value Share Analysis, by Country, 2022 and 2031

    Figure 44: North America Ophthalmic Drugs Market Attractiveness Analysis, by Country, 2023-2031

    Figure 45: North America Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031

    Figure 46: North America Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031

    Figure 47: North America Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 48: North America Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031

    Figure 49: North America Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 50: North America Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 51: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 52: North America Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 53: North America Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 54: North America Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031

    Figure 55: North America Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 56: North America Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 57: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031

    Figure 58: Europe Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 59: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 60: Europe Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031

    Figure 61: Europe Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031

    Figure 62: Europe Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 63: Europe Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031

    Figure 64: Europe Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 65: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 66: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 67: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 68: Europe Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 69: Europe Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031

    Figure 70: Europe Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 71: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 72: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031

    Figure 73: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 74: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 75: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031

    Figure 76: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031

    Figure 77: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 78: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031

    Figure 79: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 80: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 81: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 82: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 83: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 84: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031

    Figure 85: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 86: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 87: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031

    Figure 88: Latin America Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 89: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 90: Latin America Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031

    Figure 91: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031

    Figure 92: Latin America Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 93: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031

    Figure 94: Latin America Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 95: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 96: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 97: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 98: Latin America Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 99: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031

    Figure 100: Latin America Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 101: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 102: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031

    Figure 103: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 104: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 105: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031

    Figure 106: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031

    Figure 107: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 108: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031

    Figure 109: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 110: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 111: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 112: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 113: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031

    Figure 114: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031

    Figure 115: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 116: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved